03.09.2026 • News

AkzoNobel Invests €7.5 Million in New Coatings Innovation Lab

AkzoNobel opened a €7.5 million innovation lab at its Sassenheim R&D hub to speed up development of sustainable, solvent-free, energy-efficient powder coatings.

researcher in the new facility
© AkzoNobel

A new €7.5 million innovation lab has been inaugurated by AkzoNobel at its Sassenheim site in the Netherlands, strengthening the company’s largest global R&D center. The facility will focus on powder coatings and help to accelerate the development of more sustainable, solvent-free, and energy-efficient coating solutions. 

“We’ve established a global reputation for pioneering product innovation and the new lab will be pivotal in ensuring that we continue to innovate with impact,” said Frank Vergeer, R&D Director of AkzoNobel’s Powder Coatings business.  

“As well as strengthening our leadership in powder coating technologies, this investment will also expand the company’s wider innovation capabilities in coating performance, application and advanced particle analysis.” 

The new lab will mainly focus on accelerating the development of next-generation powder coatings – including lower temperature curing technologies that can further reduce energy use – as well as solutions that will support customer productivity improvements.

In-depth research will also be carried out to identify new opportunities, such as helping to extend product lifetimes, and reduce maintenance and material use. 

By developing these solutions, AkzoNobel will enhance its ability to cut carbon emissions across the value chain. The company has already reduced CO₂ emissions in its own operations (Scopes 1 and 2, baseline 2018) by 50% – four years ahead of schedule. 

Company

Logo:

AkzoNobel

Christian Neefestraat 2
1077 WW Amsterdam
Netherlands

Company contact







Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read